Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 3053.

https://doi.org/10.1182/blood-2024-210053

Published: 2024

Journal Articles

A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Catherine A. Flynn, Nina S Budano, Alexandra N. Eurell, Kirsten Meid, Andres Ramirez-Gamero, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P. Treon

Blood (2024) 144 (Supplement 1): 3011.

https://doi.org/10.1182/blood-2024-198297

Published: 2024

Journal Articles

Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

Gottfried von Keudell, Eliza A. Hawkes, Cecilia Carpio, Max S. Topp, Biyi Shen, Jingjin Li, Claire Hearnden, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry, Sabarish Ayyappan

Blood (2024) 144 (Supplement 1): 3080.

https://doi.org/10.1182/blood-2024-200623

Published: 2024

Journal Articles

A Phase 2 Trial Investigating Epcoritamab in Patients with Previously Treated Waldenstrom Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (WM-NET3)

Gottfried von Keudell, Emma K Logan, Robert A. Redd, Shayna R Sarosiek, Andrew R. Branagan, Larry D Anderson, Jr., Christopher Dittus, Steven P. Treon, Jorge J. Castillo

Blood (2024) 144 (Supplement 1): 6294.

https://doi.org/10.1182/blood-2024-206415

Published: 2024

Journal Articles

A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON)

Gottfried von Keudell, Emma K Logan, Robert A. Redd, Michael Leukam, Matthew Weinstock, Jon E. Arnason, Ranjana H. Advani

Blood (2024) 144 (Supplement 1): 6284.

https://doi.org/10.1182/blood-2024-206520

Published: 2024

Journal Articles

Infectious Complications in B-Cell Non-Hodgkin Lymphoma (NHL) Patients Treated with Bispecific Antibody Therapy (BsAb) As Compared to Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

Genevieve M Gerhard, Robert A. Redd, Poorva Bindal, Carolyn D Alonso, Rushad Patell, Michael Leukam, Jon E. Arnason, Matthew Weinstock, Gottfried von Keudell

Blood (2024) 144 (Supplement 1): 6554.

https://doi.org/10.1182/blood-2024-199156

Published: 2024

Journal Articles

Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Catherine A. Flynn, Andres Ramirez-Gamero, Nina S Budano, Alexandra N. Eurell, Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P. Treon

Blood (2024) 144 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2024-198376

Published: 2024

Journal Articles

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam

Blood (2023) 142 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2023-191921

Published: 2023

Journal Articles

Pre-Existing Cardiovascular Disease Increases the Risk of Cardiovascular Adverse Events during Bruton Tyrosine Kinase Inhibitor Therapy

Maria J. Fernandez Turizo, Eunice Kim, Aarti Asnani, Tuyen Yankama, Gottfried Von Keudell, Caroline Mejías-De Jesús

Blood (2023) 142 (Supplement 1): 496.

https://doi.org/10.1182/blood-2023-174560

Published: 2023

Journal Articles

Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies

Erika Gedvilaite, Sara DiNapoli, Coleman Spence, Monica S. Diosdado, Anna Razumova, Anita S. Bowman, Dana WY Tsui, Gilles Salles, Connie Lee Batlevi, Gottfried von Keudell, Ryan Ptashkin, Ahmet Zehir, Ryma Benayed, Michael F. Berger, A. Rose Brannon, Maria E. Arcila

Blood (2022) 140 (Supplement 1): 6430–6431.

https://doi.org/10.1182/blood-2022-167461

Published: 2022

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H Park, Eric S. Winer, Scott F. Huntington, Gottfried von Keudell, Shreya Vemuri, Madhulika Shukla, Julie C Kinoshita, Victoria Falco, Steven D. Gore, Richard M. Stone, Omar Abdel-Wahab, Martin S. Tallman

Blood (2021) 138 (Supplement 1): 43.

https://doi.org/10.1182/blood-2021-151074

Published: 2021

Journal Articles

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

Blood (2021) 138 (Supplement 1): 2447.

https://doi.org/10.1182/blood-2021-154226

Published: 2021

Journal Articles

Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade

Beatriz Wills, Laure Michaud, Heiko Schöder, Nivetha Ganesan, Craig H. Moskowitz, David J. Straus, Lorenzo Falchi, Matthew J. Matasar, Andrew D. Zelenetz, Erel Joffe, Gottfried von Keudell, Connie Lee Batlevi, Audrey Hamilton, Philip C Caron, Ariela Noy, Gilles Salles, Alison J. Moskowitz

Blood (2021) 138 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2021-153383

Published: 2021

Journal Articles

Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience

Blood (2021) 138 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2021-153171

Published: 2021

Journal Articles

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Jeffrey A. Zonder, Dahlia Sano, Michael Maris, Alexander Lesokhin, Gottfried von Keudell, Catherine Lai, Rod Ramchandren, Tina Catalano, Gloria H. Y. Lin, Bob Uger, Penka S. Petrova, Naomi Molloy, Ingmar Bruns, Swaminathan P Iyer

Blood (2021) 138 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2021-153683

Published: 2021

Journal Articles

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Blood (2021) 138 (Supplement 1): 2513.

https://doi.org/10.1182/blood-2021-151994

Published: 2021

Journal Articles

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2529.

https://doi.org/10.1182/blood-2021-147527

Published: 2021

Journal Articles

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

Blood (2021) 137 (1): 39–48.

https://doi.org/10.1182/blood.2020005112

Published: 2021

Includes: Supplemental data

Journal Articles

CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population

Paola Ghione, MD, Kurt S. Bantilan, MPH, Erel Joffe, MD MSc, M. Lia Palomba, MD, Ariela Noy, MD, Matthew J Matasar, MD, Philip Caron, MD PhD, Audrey Hamilton, MD, Paul A. Hamlin, MD, Anita Kumar, MD, Colette Owens, MD, Alison J. Moskowitz, MD, Lorenzo Falchi, MD, Gottfried von Keudell, MDPhD, Ildefonso Rodriguez-Rivera, MD, David J. Straus, MD, Steven M. Horwitz, MD, Ahmet Dogan, MD PhD, Andrew D Zelenetz, MD PhD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140757

Published: 2020

Journal Articles

Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue

Lucy Hui, Gottfried von Keudell, MD PhD, Rong Wang, PhD, Amer M. Zeidan, MBBS, MHS, Steven D. Gore, MD, Xiaomei Ma, PhD, Amy J. Davidoff, PhD, Scott F Huntington, MD MPH

Blood (2016) 128 (22): 1188.

https://doi.org/10.1182/blood.V128.22.1188.1188

Published: 2016

NARROW

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis

Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

A Phase 2 Trial Investigating Epcoritamab in Patients with Previously Treated Waldenstrom Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (WM-NET3)

A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON)

Infectious Complications in B-Cell Non-Hodgkin Lymphoma (NHL) Patients Treated with Bispecific Antibody Therapy (BsAb) As Compared to Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Pre-Existing Cardiovascular Disease Increases the Risk of Cardiovascular Adverse Events during Bruton Tyrosine Kinase Inhibitor Therapy

Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade

Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population

Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only